1 Ocak 2024 Dergi makalesi Açık Erişim

Topcu, Beril Tas; Kaplan, Ozan; Pehlivan, Sibel Bozdag; Celebier, Mustafa; Oner, Levent

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 278015, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, Ankara, Turkiye", 
      "name": "Topcu, Beril Tas"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Fac Pharm, Dept Analyt Chem, Ankara, Turkiye", 
      "name": "Kaplan, Ozan"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, Ankara, Turkiye", 
      "name": "Pehlivan, Sibel Bozdag"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Fac Pharm, Dept Analyt Chem, Ankara, Turkiye", 
      "name": "Celebier, Mustafa"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, Ankara, Turkiye", 
      "name": "Oner, Levent"
    }
  ], 
  "datePublished": "2024-01-01", 
  "description": "<p>The use of poly (ADP -ribose) polymerase (PARP) inhibitors for cancer treatment has been reported previously. Talazoparib is a PARP inhibitor, and its solubility problems encouraged us to prepare talazoparib-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles for use in brain cancer models. To determine the encapsulation efficiency and release profile, a reversed -phase high-pressure liquid chromatography (RP-HPLC) method was developed and validated. A Shiseido 5 mu m C18 100 angstrom column (250 x 4.6 mm) was used with a flow rate of 1.0 mL/min. Isocratic elution was performed using an acetonitrile:phosphate buffer (100 mm, pH 6.25) (35:65 v/v) mixture. The injection volume was 5 mu L and UV detection was performed at 227 nm. The method was linear within the range from 0.1 to 12.5 mu g/mL. The encapsulation efficiency and release profile of the prepared formulation were analyzed using the developed RP-HPLC method, and it was found that the encapsulation efficiency was 65.17% +/- 0.50 and the release of the talazoparib was around 40% within 5 h and remained stable for 25 h. The RP-HPLC method developed in the present study can be adapted for further applications to determine talazoparib in its commercial formulations and proposed encapsulated drug delivery systems.</p>", 
  "headline": "Development of an RP-HPLC method to evaluate the basic characteristics of talazoparib-loaded PLGA nanoparticles", 
  "identifier": 278015, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "license": "http://www.opendefinition.org/licenses/cc-by", 
  "name": "Development of an RP-HPLC method to evaluate the basic characteristics of talazoparib-loaded PLGA nanoparticles", 
  "url": "https://aperta.ulakbim.gov.tr/record/278015"
}